CD274 and non-small cell lung carcinoma: Given the profound impact of PD-1 and PD-L1 inhibitors on advanced NSCLC, many experts have paid great attention to investigating the potential role of ICIs in resectable NSCLC, and several undergoing clinical trials have reported promising results (8–11).